50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to empower physicians globally to deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination protocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-05-1488% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1872% match
“Our mission is to design, develop and commercialize medical products that enable the collection, processing and cryopreservation of stem cells and other cellular tissues used in the practice of regenerative medicine.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-09-1172% match
“Our mission is to advance to market novel regenerative medicine and cellular therapy products that substantially benefit humankind.”In use 2016 – now·1 sighting·SEC Form S-1/A, filed 2016-02-0272% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2471% match
“Our mission is to revolutionize regenerative medicine by bioengineering patient-specific Cellspan implants that use the patient’s own mesenchymal stromal cells to stimulate organ regeneration and restore an organ’s structure and continuity.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-04-1371% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2570% match
“Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2770% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2870% match
“Our mission is to become the market leader in providing innovative technologies that enable physicians to improve the lives of millions of women.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2269% match
“Our mission is to significantly improve patient outcomes and address areas of high unmet medical need with our nanotechnology-based therapies.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-12-1169% match
“Our mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.”In use 2011 – now·1 sighting·SEC Form S-1, filed 2011-02-0169% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0869% match
“Our mission is to develop disease-modifying, regenerative therapies to restore vision to millions of patients.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-01-2469% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1169% match
“Our mission is to reimagine therapeutics and their delivery.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-0169% match
“Our mission is to develop next generation cell and gene therapeutics with the capacity to cure.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0769% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1269% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2269% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2869% match
“Our mission is to enable the future of medicine for a new era of life sciences.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0769% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0169% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1969% match
“Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-2069% match
“Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1768% match
“Our mission is to empower researchers and clinicians to advance science and medicine.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1868% match
“Our mission is to accelerate transformative therapies to improve the lives of people living with cancer and other serious diseases.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2368% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1568% match
“Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2568% match
“Our mission is to translate complex, powerful biology with rigor and urgency into life-changing medicines.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1168% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0468% match
“Our mission is to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-06-2268% match
“Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2368% match
“Our mission is to leverage our existing and expanding network of academic and industry leaders and investors, including venture capital and private equity, in major healthcare markets globally to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-06-1068% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2368% match
“Our mission is to develop innovative, transformative therapies for patients with devastating diseases through the use of our novel chRDNA genome-editing technology.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0568% match
“Our mission is to deliver transformative therapeutics to those in need, and we believe our innovative EDO technology is well-positioned to effect this change for patients, families and the broader healthcare community.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0468% match
“Our mission is to use our technology to create a new generation of RNAi therapeutics which can improve outcomes for patients.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-09-0867% match
“Our mission is to create medicines that make a difference for patients, build value for our fellow stockholders, and empower our passionate team.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-02-2267% match
“Our mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2467% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0567% match
“Our mission is to transform the lives of patients living with devastating genetic diseases by building the leading integrated genetic medicine company focused on developing and commercializing potentially curative therapeutics based on our GeneRide platform.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-1567% match
“Our mission is to enrich clinical practice and the patient/consumer experience by developing and commercializing topically applied products which offer the benefits of our advanced bioactive small molecule peptide technology.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-2767% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0967% match
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1267% match
“Our mission is to provide access to high-quality, innovative, impactful, and affordable medicines to billions more people globally.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-02-2567% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0167% match
“Our mission is to transform the lives of patients with rare genetic diseases using our ex vivo autologous HSC gene therapy approach.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2767% match
“Our mission is to improve health for all with great, innovative, affordable medicines so that people with life-changing or chronic conditions can gain access to the medicines they need, physicians can treat patients without barriers to prescribing, and health systems can afford to make those medicines available, without restrictions, to the populations they serve in a financially sustainable manner.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2367% match
Showing 1–50 of 50